Literature DB >> 8704210

The effect of the Fanconi anemia polypeptide, FAC, upon p53 induction and G2 checkpoint regulation.

G M Kupfer1, A D D'Andrea.   

Abstract

Fanconi anemia (FA) is an autosomal recessive disease marked by developmental defects, bone marrow failure, and cancer susceptibility. FA cells are hypersensitive to DNA cross-linking and alkylating agents and accumulate in the G2 phase of the cell cycle in response to these agents. FA cells also display genomic instability, suggesting a possible defect in the p53 pathway. To test the effect of heterologous expression of FAC cDNA on drug-induced cytotoxicity, G2 accumulation, and p53 induction in FA cells, we compared two isogenic FA cell lines: HSC536N (mock), a FA type C cell line sensitive to mitomycin C (MMC), and the same cell line transfected (corrected) with wild-type FAC cDNA (HSC536N [+FAC]). HSC536N (+FAC) cells showed a 30-fold increase in resistance to MMC concentration. Similarly, increases in resistance were observed following exposure to cisplatin, carboplatin, and cyclophosphamide. In addition, HSC536N (+FAC) cells showed a twofold lower G2 accumulation following MMC treatment. To analyze the possible interaction of FAC with the p53 pathway, we analyzed p53 induction in mock and corrected cell lines following exposure to MMC. HSC536N (mock) cells induced p53 at lower MMC concentrations than HSC536N (corrected). Caffeine, a known G2 checkpoint inhibitor, not only inhibited G2 accumulation seen in both cell lines but also caused the resistant HSC536N (+FAC) to become as sensitive to MMC as HSC536N (mock) cell line. We conclude that the FAC protein has a specific cytoprotective effect and may function as a cell cycle regulator of the G2 phase of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8704210

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells.

Authors:  Raphael Ceccaldi; Kalindi Parmar; Enguerran Mouly; Marc Delord; Jung Min Kim; Marie Regairaz; Marika Pla; Nadia Vasquez; Qing-Shuo Zhang; Corinne Pondarre; Régis Peffault de Latour; Eliane Gluckman; Marina Cavazzana-Calvo; Thierry Leblanc; Jérôme Larghero; Markus Grompe; Gérard Socié; Alan D D'Andrea; Jean Soulier
Journal:  Cell Stem Cell       Date:  2012-06-07       Impact factor: 24.633

2.  Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.

Authors:  Raphael Ceccaldi; Delphine Briot; Jérôme Larghero; Nadia Vasquez; Catherine Dubois d'Enghien; Delphine Chamousset; Maria-Elena Noguera; Quinten Waisfisz; Olivier Hermine; Corinne Pondarre; Thierry Leblanc; Eliane Gluckman; Hans Joenje; Dominique Stoppa-Lyonnet; Gérard Socié; Jean Soulier
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

Review 3.  Molecular pathogenesis of Fanconi anemia.

Authors:  Natalie Collins; Gary M Kupfer
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

4.  Fanconi anemia proteins and endogenous stresses.

Authors:  Qishen Pang; Paul R Andreassen
Journal:  Mutat Res       Date:  2009-07-31       Impact factor: 2.433

Review 5.  Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights.

Authors:  Larry H Thompson; John M Hinz
Journal:  Mutat Res       Date:  2009-02-21       Impact factor: 2.433

6.  Complementation of hypersensitivity to DNA interstrand crosslinking agents demonstrates that XRCC2 is a Fanconi anaemia gene.

Authors:  Helmut Hanenberg; Paul R Andreassen; Jung-Young Park; Elizabeth L Virts; Anna Jankowska; Constanze Wiek; Mohamed Othman; Sujata C Chakraborty; Gail H Vance; Fowzan S Alkuraya
Journal:  J Med Genet       Date:  2016-05-20       Impact factor: 6.318

Review 7.  Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy.

Authors:  Paul R Andreassen; Keqin Ren
Journal:  Curr Cancer Drug Targets       Date:  2009-02       Impact factor: 3.428

8.  FANCG is phosphorylated at serines 383 and 387 during mitosis.

Authors:  Jun Mi; Fengyu Qiao; James B Wilson; Anthony A High; Melanie J Schroeder; Peter T Stukenberg; Amy Moss; Jeffrey Shabanowitz; Donald F Hunt; Nigel J Jones; Gary M Kupfer
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

9.  Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis.

Authors:  H L Ford; E N Kabingu; E A Bump; G L Mutter; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

10.  The FANCJ/MutLalpha interaction is required for correction of the cross-link response in FA-J cells.

Authors:  Min Peng; Rachel Litman; Jenny Xie; Sudha Sharma; Robert M Brosh; Sharon B Cantor
Journal:  EMBO J       Date:  2007-06-21       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.